An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing (NCT06306521)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to test a new method for newborn screening using whole genome sequencing, called BeginNGS. Parents will be approached to provide informed consent to enroll their newborns in prenatal, postnatal, and outpatient settings. The main questions this study aims to answer are: What is the utility of BeginNGS as compared to state newborn screening? What is the acceptability and feasibility of BeginNGS as compared to state newborn screening? What is the cost effectiveness of BeginNGS as compared to state newborn screening? Enrolled newborns will have a blood sample taken and will receive the BeginNGS test. Newborns will have also had the state newborn screening test.
Who can join: Review the eligibility criteria below.
Location: Rady Children's Hospital San Diego — San Diego, California
Age range: 1 Day to 28 Days
🧪 Interventions in This Study
- BeginNGS Test (GENETIC)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Rady Children's Hospital San Diego — San Diego, California
📞 Contact the Study Coordinator
Phone: (858) 576-1700
Email: lolsen1@rchsd.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Genetic Disease
- Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease — Nashville, Tennessee
- Diagnostic Odyssey: Whole Genome Sequencing (WGS) — Miami, Florida
- The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment — Birmingham, Alabama
- Penn Medicine Biobank Return of Results Program — Philadelphia, Pennsylvania
- An Open-label, Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for TUBB4A-related Leukodystrophy — San Diego, California
- Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A — San Diego, California
Explore by condition: All Genetic Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.